secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-076522
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax Q4 Revuforj $44.2M (+38% QoQ); Niktimvo $56M; net loss $68M
------------------------------------------------------------------

- Total revenue $68.7M in Q4 and $172.4M in FY2025, driven by Revuforj and Niktimvo launches.
- Revuforj net revenue $44.2M in Q4 (+38% vs Q3) and $124.8M in FY2025; ~1,150 prescriptions in Q4.
- Niktimvo net revenue $56M in Q4 (+22% vs Q3) and $151.6M in FY2025; Syndax collaboration revenue $42.4M FY.
- Net loss $68M (0.78/share) in Q4 and $285.4M ($3.29/share) for FY2025; cash $394.1M at year-end.
- FY2026 opex guidance ~$400M ex-stock comp; expects profitability from cash, revenue, and interest income.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000119312526076522/0001193125-26-076522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000119312526076522/sndx-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-076522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer